InStride Health Raises Oversubscribed $30 Million Series B to Expand Access to Best-In-Class Specialty Treatment for Pediatric Anxiety and OCD

InStride In The News

Press Releases

InStride Health Series B Announcement

Series B Press Release

General Catalyst leads funding round joined by .406 Ventures, Valtruis, Mass General Brigham Ventures, and Hopelab Foundation to bolster insurance-based mental health program availability in new markets.

Read Full Release »
Outcomes Press Release

First Annual Outcomes Report

InStride Health, a specialty pediatric anxiety and OCD treatment provider, released its first annual outcomes report. Based on treatment of over 350 patients, InStride Health demonstrated clinically meaningful results of its coordinated care model.

Read Full Release »

Series B Press Release

General Catalyst leads funding round joined by .406 Ventures, Valtruis, Mass General Brigham Ventures, and Hopelab Foundation to bolster insurance-based mental health program availability in new markets.

Read More »

First Annual Outcomes Report

InStride Health, a specialty pediatric anxiety and OCD treatment provider, released its first annual outcomes report. Based on treatment of over 350 patients, InStride Health demonstrated clinically meaningful results of its coordinated care model.

Read More »

Media Kit

InStride Health Co-Founders

Founding Partners 1

InStride Health Co-Founders

Founding Partners 2

Founding Clinicians 1

Founding Clinicians 2

InStride Health Team

Team Photo

About InStride Health

About Us

Mona Potter Bio

Leadership Bios

Press Inquiries

If you are a member of the press and would like to feature InStride Health, speak to an InStride Health representative or need high-resolution photos, please contact:

Alexis Ducharme 

855.438.8331 ext: 751

If you have a question or comment.

If you are ready to start the application process.